MINERVA NEUROSCIENCES INC (NERV) Fundamental Analysis & Valuation

NASDAQ:NERV • US6033802058

Current stock price

5.23 USD
-0.05 (-0.95%)
At close:
5.23 USD
0 (0%)
After Hours:

This NERV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NERV Profitability Analysis

1.1 Basic Checks

  • NERV had negative earnings in the past year.
  • NERV had a negative operating cash flow in the past year.
  • NERV had negative earnings in 4 of the past 5 years.
  • NERV had a negative operating cash flow in each of the past 5 years.
NERV Yearly Net Income VS EBIT VS OCF VS FCFNERV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • NERV's Return On Assets of -299.51% is on the low side compared to the rest of the industry. NERV is outperformed by 92.07% of its industry peers.
Industry RankSector Rank
ROA -299.51%
ROE N/A
ROIC N/A
ROA(3y)-35.71%
ROA(5y)-33.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NERV Yearly ROA, ROE, ROICNERV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

  • NERV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NERV Yearly Profit, Operating, Gross MarginsNERV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 1 2 3 4

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. NERV Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for NERV has been increased compared to 1 year ago.
  • NERV has more shares outstanding than it did 5 years ago.
  • NERV has a better debt/assets ratio than last year.
NERV Yearly Shares OutstandingNERV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
NERV Yearly Total Debt VS Total AssetsNERV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -8.78, we must say that NERV is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -8.78, NERV is not doing good in the industry: 71.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.78
ROIC/WACCN/A
WACCN/A
NERV Yearly LT Debt VS Equity VS FCFNERV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 36.28 indicates that NERV has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 36.28, NERV belongs to the top of the industry, outperforming 98.45% of the companies in the same industry.
  • NERV has a Quick Ratio of 36.28. This indicates that NERV is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 36.28, NERV belongs to the best of the industry, outperforming 98.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 36.28
Quick Ratio 36.28
NERV Yearly Current Assets VS Current LiabilitesNERV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NERV Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 31.55% over the past year.
EPS 1Y (TTM)31.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.95% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.15%
EPS Next 2Y32.5%
EPS Next 3Y21.96%
EPS Next 5Y16.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NERV Yearly Revenue VS EstimatesNERV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2028 2029 2030 2031 50M 100M 150M 200M 250M
NERV Yearly EPS VS EstimatesNERV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. NERV Valuation Analysis

4.1 Price/Earnings Ratio

  • NERV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NERV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NERV Price Earnings VS Forward Price EarningsNERV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NERV Per share dataNERV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NERV's earnings are expected to grow with 21.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.5%
EPS Next 3Y21.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NERV Dividend Analysis

5.1 Amount

  • No dividends for NERV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NERV Fundamentals: All Metrics, Ratios and Statistics

MINERVA NEUROSCIENCES INC

NASDAQ:NERV (4/6/2026, 8:00:02 PM)

After market: 5.23 0 (0%)

5.23

-0.05 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11
Earnings (Next)05-11
Inst Owners68.19%
Inst Owner Change0%
Ins Owners0.65%
Ins Owner Change0%
Market Cap226.30M
Revenue(TTM)N/A
Net Income(TTM)-293.42M
Analysts45.71
Price Target7.4 (41.49%)
Short Float %1.34%
Short Ratio2.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)61.11%
PT rev (3m)61.11%
EPS NQ rev (1m)7.14%
EPS NQ rev (3m)7.14%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.32
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0
BVpS-3.14
TBVpS-3.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -299.51%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.71%
ROA(5y)-33.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 36.28
Quick Ratio 36.28
Altman-Z -8.78
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y51.15%
EPS Next 2Y32.5%
EPS Next 3Y21.96%
EPS Next 5Y16.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.24%
OCF growth 3YN/A
OCF growth 5YN/A

MINERVA NEUROSCIENCES INC / NERV Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MINERVA NEUROSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to NERV.


What is the valuation status of MINERVA NEUROSCIENCES INC (NERV) stock?

ChartMill assigns a valuation rating of 1 / 10 to MINERVA NEUROSCIENCES INC (NERV). This can be considered as Overvalued.


What is the profitability of NERV stock?

MINERVA NEUROSCIENCES INC (NERV) has a profitability rating of 0 / 10.


Can you provide the financial health for NERV stock?

The financial health rating of MINERVA NEUROSCIENCES INC (NERV) is 4 / 10.